Jan Cerny

Jan Cerny, MD, PhD is an Associate Professor in the Department of Medicine at UMass Chan Medical School, specializing in Hematology/Oncology within the Division of Hematology/Oncology at the T.H. Chan School of Medicine. His academic career has been focused on clinical and translational research in hematology, particularly in the areas of hematopoietic cell transplantation, myeloid malignancies, and acute myeloid leukemia.

Dr. Cerny received his MD and PhD in Medicine from Charles University in Prague, Czech Republic, establishing a strong foundation in both clinical medicine and scientific research. His educational background has positioned him well for his current role in academic hematology where he combines patient care with research.

Dr. Cerny's research primarily focuses on hematopoietic cell transplantation outcomes, myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and the impact of genetic mutations on disease progression and treatment response. His work frequently examines TP53 disruptions, clonal dynamics in hematological malignancies, and the effectiveness of various transplantation protocols. He has contributed significantly to understanding how different conditioning regimens, mutation profiles, and patient characteristics affect transplantation outcomes.

His publication record demonstrates a consistent focus on clinical outcomes research in hematological malignancies, with numerous studies analyzing data from the Center for International Blood and Marrow Transplant Research (CIBMTR). Recent work has examined frameshift mutations in leukemia-associated genes, trends in transplantation among racial/ethnic minorities, and real-world effectiveness of targeted therapies like midostaurin for FLT3-mutated AML.

Dr. Cerny has been actively involved in multi-institutional collaborative research, frequently publishing with large consortia that analyze registry data to answer important clinical questions in hematology and transplantation medicine. His work bridges basic science discoveries with clinical applications, aiming to improve outcomes for patients with complex hematological conditions.